The evolving landscape of untargeted metabolomics

Area of Science:

• Metabolomics
• Biomarker Discovery
• Translational Science

Background:

• Untargeted metabolomics serves as a hypothesis-generating strategy for comparing sample groups and identifying metabolic perturbations.
• Targeted metabolomics provides crucial data for life sciences and novel treatment strategies for major diseases.
• Improving the translational potential of untargeted metabolomics is a current focus due to its biomarker discovery relevance.

Purpose of the Study:

• To enhance the translational potential of untargeted metabolomics for biomarker discovery.
• To address challenges in metabolite profiling and clinical validation for untargeted metabolomics.
• To support the development of biomarkers for personalized treatment strategies.

Main Methods:

• Utilizing expertise in laboratory medicine and bioinformatics to overcome metabolite profiling challenges.
• Focusing on clinical validation, including instrument reliability and test profitability.
• Exploring miniaturized, low-cost, mobile devices for metabolite analysis, similar to existing ELISA kits.

Main Results:

• Expertise in laboratory medicine and bioinformatics can mitigate biases in untargeted metabolomics.
• Clinical validation and profitability are essential for the progression of potential biomarkers.
• Biomarkers are being developed for personalized patient response and optimal treatment strategies.

Conclusions:

• Enhanced understanding of disease pathophysiology will positively impact untargeted metabolomics applications.
• Miniaturized, user-friendly approaches are needed, supported by regulatory guidelines.
• Addressing uncertainties regarding miniaturized instruments and software will boost regulatory and patient acceptance.